Researchers engineered GFD-CD3, a bispecific T-cell engager that directs cytotoxic T cells to uPAR-positive senescent cells using the natural ligand domain of uPA as its targeting arm. High doses produced hepatotoxicity through T-cell attack on hepatic endothelial cells, while low doses guided by serum transaminase monitoring cleared senescent cells and reduced age-related pathology in aged mice and non-human primates without adverse effects. The dose-titratability of the engager addresses the principal translational obstacle of senolytic CAR-T approaches.
Key Points
- Bispecific engager cleared uPAR-positive senescent cells in mice and primates
- High doses injured hepatic endothelial cells; low doses proved safe
- Serum transaminase levels served as practical dose-limiting safety marker
Longevity Analysis
Senescent cell burden drives chronic inflammatory signaling that distorts communication across immune, metabolic, and repair pathways, and removing that burden has become one of the more credible interventions in aging biology. Directing the body's own defensive machinery against these cells, rather than relying on small molecules with broad off-target activity, offers precision — but the hepatic endothelium emerges here as the tissue most vulnerable to overshoot, making liver enzyme surveillance the operational boundary between clearance and injury. The finding that a measurable blood marker defines the therapeutic window is as consequential as the agent itself, since it converts an unpredictable cellular therapy into a titratable, monitorable protocol.
Original published by Wiley Aging Cell, by Jian Deng, Xiaozhu Zeng, Jing Guo, Lihong Li, Shirui Zou, Nan Liu, Shuai He, Lanzhen Yan, Qiong Wang, Yongjie Zhu, Ben Wang, Dong Yang, Longbao Lv, Xudong Zhao .